TransMedics Group, Inc.·4

Dec 16, 4:30 PM ET

DAMME LAURA 4

4 · TransMedics Group, Inc. · Filed Dec 16, 2022

Insider Transaction Report

Form 4
Period: 2022-12-14
DAMME LAURA
VP, Clinical Affairs
Transactions
  • Exercise/Conversion

    Common Stock

    2022-12-14$38.46/sh+5,947$228,7225,947 total
  • Sale

    Common Stock

    2022-12-15$58.96/sh4,740$279,4700 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-12-154,74014,063 total
    Exercise: $38.46Exp: 2031-02-24Common Stock (4,740 underlying)
  • Exercise/Conversion

    Common Stock

    2022-12-15$38.46/sh+250$9,615250 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-12-145,94719,053 total
    Exercise: $38.46Exp: 2031-02-24Common Stock (5,947 underlying)
  • Sale

    Common Stock

    2022-12-14$62.43/sh5,947$371,2710 total
  • Sale

    Common Stock

    2022-12-15$60.02/sh250$15,0050 total
  • Exercise/Conversion

    Common Stock

    2022-12-15$38.46/sh+4,740$182,3004,740 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-12-1525018,803 total
    Exercise: $38.46Exp: 2031-02-24Common Stock (250 underlying)
Footnotes (4)
  • [F1]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $62.00 to $62.91, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F2]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $60.00 to $60.35, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F3]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $58.92 to $59.32, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F4]The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION